147 related articles for article (PubMed ID: 37959672)
1. Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies.
Hashem HE; Amr AEE; Almehizia AA; Naglah AM; Kariuki BM; Eassa HA; Nossier ES
Molecules; 2023 Oct; 28(21):. PubMed ID: 37959672
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
5. Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents.
Bagul C; Rao GK; Veena I; Kulkarni R; Tamboli JR; Akunuri R; Shaik SP; Pal-Bhadra M; Kamal A
Mol Divers; 2023 Jun; 27(3):1185-1202. PubMed ID: 36114912
[TBL] [Abstract][Full Text] [Related]
6. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies.
Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R
Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490
[TBL] [Abstract][Full Text] [Related]
7. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
8. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
10. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
11. The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography,
Musa A; Ihmaid SK; Hughes DL; Said MA; Abulkhair HS; El-Ghorab AH; Abdelgawad MA; Shalaby K; Shaker ME; Alharbi KS; Alotaibi NH; Kays DL; Taylor LJ; Parambi DGT; Alzarea SI; Al-Karmalawy AA; Ahmed HEA; El-Agrody AM
J Biomol Struct Dyn; 2023; 41(21):12411-12425. PubMed ID: 36661285
[TBL] [Abstract][Full Text] [Related]
12. Novel 2-Sulfanylquinazolin-4(3
Altharawi A; Alanazi MM; Alossaimi MA; Alanazi AS; Alqahtani SM; Geesi MH; Riadi Y
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513420
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and
Mandour AA; Nassar IF; Abdel Aal MT; Shahin MAE; El-Sayed WA; Hegazy M; Yehia AM; Ismail A; Hagras M; Elkaeed EB; Refaat HM; Ismail NSM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1957-1973. PubMed ID: 35815597
[TBL] [Abstract][Full Text] [Related]
14. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
16. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening.
Elkamhawy A; Ammar UM; Paik S; Abdellattif MH; Elsherbeny MH; Lee K; Roh EJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500757
[TBL] [Abstract][Full Text] [Related]
17. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
[TBL] [Abstract][Full Text] [Related]
18. Novel 5-bromoindole-2-carboxylic Acid Derivatives as EGFR Inhibitors: Synthesis, Docking Study, and Structure Activity Relationship.
Hassan OM; Kubba A; Tahtamouni LH
Anticancer Agents Med Chem; 2023; 23(11):1336-1348. PubMed ID: 36847231
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new 1
Gaber AA; Sobhy M; Turky A; Abdulwahab HG; Al-Karmalawy AA; Elhendawy MA; Radwan MM; Elkaeed EB; Ibrahim IM; Elzahabi HSA; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2283-2303. PubMed ID: 36000168
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
